Wegovy® (semaglutide) injection

Wegovy (semaglutide) is a once weekly prescription injectable medication designed to support long-term weight management in adults and certain adolescents with obesity, or adults who are overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. It works by mimicking the GLP-1 hormone to help regulate appetite, increase feelings of fullness, and reduce calorie intake.

Available Strengths

• 0.25 mg
• 0.5 mg
• 1 mg
• 1.7 mg
• 2.4 mg
• 7.2 mg (Wegovy HD)

Typical Dosing Schedule

• Weeks 1–4: 0.25 mg once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance dose)
• For eligible patients who require additional weight loss after treatment with 2.4 mg, a healthcare provider may recommend transitioning to Wegovy HD 7.2 mg.

Common Side Effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Stomach pain
• Headache
• Fatigue

These side effects are generally mild to moderate and often improve as your body adjusts to the medication.

Benefits

• Supports significant and sustained weight loss when combined with a reduced-calorie diet and increased physical activity.
• Helps reduce appetite and food cravings.
• May improve blood sugar control in people with type 2 diabetes.
• Can lower the risk of certain cardiovascular events in eligible adults with obesity or overweight and established cardiovascular disease.

Important Safety Information

Wegovy should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is not recommended during pregnancy. Always use Wegovy exactly as prescribed by your healthcare provider.